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Aims The present study sought to assess the impact of aortic stenosis (AS) on myocardial function as assessed by layer-




We compared 211 patients (56% males, mean age 73 ± 12 years) with severe AS and left ventricular ejection frac-
tion (LVEF) >_50% (114 symptomatic, 97 asymptomatic) with 50 controls matched for age and sex. LS was assessed
from endocardium, mid-myocardium, and epicardium by 2D speckle-tracking echocardiography. Despite similar
LVEF, multilayer strain values were significantly lower in symptomatic patients, compared to asymptomatic and
controls [global LS: 17.9 ± 3.4 vs. 19.1 ± 3.1 vs. 20.7 ± 2.1%; endocardial LS: 20.1 ± 4.9 vs. 21.7 ± 4.2 vs. 23.4 ± 2.5%;
epicardial LS: 15.8 ± 3.1 vs. 16.8 ± 2.8 vs. 18.3 ± 1.8%; P < 0.001 for all]. On multivariable logistic regression analysis,
endocardial LS was independently associated to symptoms (P = 0.012), together with indexed left atrial volume
(P = 0.006) and LV concentric remodelling (P = 0.044). During a mean follow-up of 22 months, 33 patients died of a
cardiovascular event. On multivariable Cox-regression analysis, age (P = 0.029), brain natriuretic peptide values
(P = 0.003), LV mass index (P = 0.0065), LV end-systolic volume (P = 0.012), and endocardial LS (P = 0.0057)
emerged as independently associated with cardiovascular death. The best endocardial LS values associated with
outcome was 20.6% (sensitivity 70%, specificity 52%, area under the curve = 0.626, P = 0.022). Endocardial LS
(19.1 ± 3.3 vs. 20.7 ± 3.3, P = 0.02) but not epicardial LS (15.2 ± 2.8 vs. 15.9 ± 2.5, P = 0.104) also predicted the out-
come in patients who were initially asymptomatic.
...................................................................................................................................................................................................
Conclusion In patients with severe AS, LS impairment involves all myocardial layers and is more prominent in the advanced
phases of the disease, when the symptoms occur. In this setting, the endocardial LS is independently associated
with symptoms and patient outcome.
! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
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Introduction
Aortic stenosis (AS) is currently the most common valvular heart dis-
ease, and its prevalence is increasing as the population ages.1
Symptomatic patients with severe AS have a high mortality rate and
require prompt aortic valve replacement (AVR).2,3 Although asymp-
tomatic patients are at increased risk for untoward events, their man-
agement remains controversial. Current guidelines consider AVR as
reasonable in asymptomatic patients with reduced (<50%) left ven-
tricular ejection fraction (LVEF) and in patients who exhibit
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..symptoms during an exercise test.4,5 However, symptoms are sub-
jective and LVEF can remain normal for long despite markedly
impaired myocardial function. We previously demonstrated that 2D
LV global longitudinal strain (GLS) could detect early subtle myocar-
dial dysfunction in AS patients.6–9 The impairment of global LV longi-
tudinal function is associated with myocardial fibrosis, which is, in
turn, a potential prognostic marker in patients with AS.10 However,
longitudinal function is actually largely governed by the subendocar-
dial myocardial fibres, which are affected first by the pathological
changes (hypertrophy, increased wall stress, and reduced arterial
compliance) associated with AS.11,12 Recent 2D strain software
allows separate evaluation of endocardial, mid-myocardial, and epi-
cardial myocardial deformation. To date, little is known about the im-
pact of AS on the different myocardium layers. The present study
sought to investigate the relationship between changes in layer-




A total of 249 patients with severe AS who were prospectively examined
in our heart valve clinic between January 2007 and February 2018 were
evaluated. Inclusion criteria were severe AS defined by an aortic valve
area <_0.6 cm2/m2 by echocardiography, normal LVEF (>_50%) as calcu-
lated by 2D echocardiography, no more than mild associated cardiac
valve lesion, sinus rhythm, and good images quality. Thirty-nine patients
were excluded for suboptimal quality of speckle-tracking image analysis.
The final study population consisted of 211 patients, which were divided
into two groups, according to the symptomatic status. The control group
included 50 patients matched for age and sex. All patients gave written
informed consent and the hospital ethics committee approved the study.
Echocardiographic measurements
Transthoracic echocardiograms were performed using a Vivid ultrasound
(7, E9 or E95) System (GE Healthcare, Horten, Norway) and stored on a
dedicate workstation for off-line analysis (EchoPAC, version 201, GE
Healthcare). For each echocardiographic measurement, at least two car-
diac cycles were averaged. Conventional echocardiographic measure-
ments were performed in accordance with the guidelines.13–15 Valvulo-
arterial impedance (Zva) was calculated as the sum of systolic blood
pressure and mean transaortic gradient, divided by indexed LV stroke
volume. Strain analysis was based on speckle-tracking approach, meas-
ured by an experienced cardiologist and expressed as an absolute value.
The acquisitions were performed in apical long-axis, four-, and two-
chamber views (frame rate 70–90 frames/s).16,17 LV was divided into six
myocardial segments in each view, and GLS calculated as the average LS
at end-systole. For measuring layer-specific strain, attention was taken to
cover the entire myocardial wall thickness by the region of interest (ROI)
of each segment. Calculation of transmural variation of LS across the en-
tire myocardium was based on the assumption of a linear distribution.
Endocardial and epicardial LS were measured on the endocardial and epi-
cardial ROI border, respectively, whereas the mid (centre line) of the
ROI represented the average values of the transmural wall thickness
(GLS). LS gradient was calculated as the difference between endocardial
and epicardial LS.18 Right ventricle (RV) LS was calculated as the average
of regional strain from RV free wall segments and interventricular
septum.
Clinical follow-up
Patients were routinely followed-up and managed according to available
guidelines, and clinical information was obtained from direct patient inter-
view, telephone calls with physicians, patients, or next of kin, or review of
autopsy records and death certificates. Cardiovascular-related mortality
was the endpoint.
Statistical analysis
Data are reported as mean ± standard deviation for continuous variables
or percentages of individuals for categorical variables. The v2 test or
Fisher’s exact test was used to compare qualitative variables. One-way
analysis of variance test was used to compare the three groups. When a
significant difference was found, post hoc testing with Bonferroni compari-
sons for identified specific group differences was used. Variables with a
P-value <0.05 on univariable analysis were incorporated into the multi-
variable logistic regression model for the prediction of symptoms and car-
diovascular mortality. Receiver operator characteristics (ROC) curves
were generated to determine the cut-off value that best predicted the oc-
currence of symptoms and cardiovascular mortality. The Kaplan–Meier
method was used for cumulative survival analysis with the log-rank test
for assessing statistical differences between the curves. Statistical analyses
were performed using IBM-SPSS, version 23 (SPSS Inc., Chicago, IL, USA).
Reproducibility analyses were previously published by our group.17,19
Results
Baseline patients’ characteristics
Of the 211 patients, 114 (54%) were classified as symptomatic base-
line (syncope = 4, dyspnoea = 98, angina = 7, and acute pulmonary
oedema = 5) (Table 1). Compared with the 97 (56%) asymptomatic
patients, they did not differ in age, gender, LV ejection fraction, and
presence of risk factors but had higher body mass index, systolic
blood pressure, aortic pressure gradients, brain natriuretic peptide
(BNP) levels, and smaller aortic valve area. Symptomatic patients also
had more pronounced cardiac chambers remodelling, diastolic dys-
function, and impaired RV function. Despite similar LV ejection frac-
tion between groups, multilayer strain values (GLS, endocardial,
epicardial, and gradient LS) were significantly lower in symptomatic
patients (Figure 1). Asymptomatic patients also had lower strain val-
ues when compared with controls. In all groups, endocardial systolic
strain was higher than epicardial strain.
Symptomatic vs. asymptomatic AS
The impact of specific layer strains on symptoms was evaluated in
two multivariable models, where GLS was taken as the reference
(GLS vs. endocardial LS or epicardial LS). In the first model, concen-
tric remodelling [P = 0.044, odds ratio (OR) = 2.294], indexed left
atrial volume (P = 0.006, OR = 1.035), and endocardial LS (P = 0.012,
OR = 1.150) emerged as independent cofactors associated with
symptoms after adjustment for body mass index, BNP level, types of
remodelling, and severity of AS (Table 2). In the second model, con-
centric remodelling (P = 0.04, OR = 2.429), indexed left atrial volume
(P = 0.006, OR = 1.036), and GLS (P = 0.015, OR = 1.17) emerged as
independent cofactors associated with symptoms after adjustment
for body mass index, BNP level, LV mass, types of remodelling, and
severity of AS (Table 3). At ROC curve analysis (Figure 2), a
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AS group (n 5 97)
Symptomatic
AS group (n 5 114)
P-value
Clinical variables
Age (years) 71.1 ± 4.7 71.9 ± 12.2 74.9 ± 11.0 0.071
Male gender, n (%) 25 (50) 55 (57) 64 (56) 0.713
Body mass index (kg/m2) 25.5 ± 3.4 26.1 ± 4.0 27.8 ± 5.8a,b 0.007
Body surface area (m2) 1.8 ± 0.2 1.8 ± 0.2 1.8 ± 0.2 0.472
Systolic arterial pressure (mmHg) 128 ± 11 137 ± 18a 135 ± 20 0.028
Diastolic arterial pressure (mmHg) 77 ± 8 73 ± 10 73 ± 11 0.052
BNP (log) 4.4 ± 1.1 4.9 ± 1.1b 0.007
Diabetes mellitus, n (%) 20 (21) 30 (26) 0.353
Hypertension, n (%) 69 (73) 89 (78) 0.362
Hypercholesterolaemia, n (%) 64 (67) 74 (65) 0.790
Current smoking, n (%) 15 (16) 16 (14) 0.746
Coronary artery disease, n (%) 10 (10) 21 (19) 0.092
LV dimensions and geometry
Interventricular septum (mm) 9.6 ± 1.2 12.2 ± 2.0a 13.7 ± 2.4a,b <0.001
LV posterior wall (mm) 9.8 ± 1.9 10.6 ± 1.6a 11.5 ± 1.7a,b <0.001
LV end-diastolic diameter (mm) 42.7 ± 5.3 44.9 ± 5.9 45.5 ± 6.2a 0.023
LV end-systolic diameter (mm) 29.3 ± 5.1 30.1 ± 6.0 29.8 ± 5.7 0.732
LV mass index (g/m2) 76.8 ± 20.2 103.7 ± 27.2a 120.0 ± 27.5a,b <0.001
Relative wall thickness 0.46 ± 0.1 0.48 ± 0.10 0.51 ± 0.11a 0.019
Normal geometry, n (%) 19 (38) 19 (23)a 10 (10)a,b <0.001
Concentric remodelling, n (%) 25 (50) 30 (36)a 19 (18)a,b <0.001
Concentric hypertrophy, n (%) 5 (10) 26 (31)a 62 (60)a,b <0.001
Eccentric hypertrophy, n (%) 1 (2) 9 (11) 13 (12) 0.109
Aortic valve severity
Mean pressure gradient (mmHg) 43.8 ± 12.9 47.7 ± 14.4b 0.044
Peak aortic velocity (m/s) 4.2 ± 0.6 4.3 ± 0.6 0.143
Aortic valve area (cm2) 0.81 ± 0.15 0.78 ± 0.20 0.153
Indexed aortic valve area (cm2/m2) 0.45 ±0.08 0.42 ± 0.09b 0.017
Indexed stroke volume (mL/m2) 45.5 ± 10.0 44.7 ± 9.2 0.554
Zva (mmHg/mL/m2) 4.2 ± 1.0 4.3 ± 1.0 0.530
Low flow–low gradient, n (%) 11 (11) 7 (6) 0.184
low flow–high gradient, n (%) 4 (4) 8 (7) 0.358
Normal flow–low gradient, n (%) 22 (23) 17 (15) 0.156
Normal flow–high gradient, n (%) 60 (62) 79 (70) 0.219
LV-RV dimension function
LV end-diastolic volume (mL) 83.0 ± 24.3 89.8 ± 31.8 94.7 ± 34.8 0.138
LV end-systolic volume (mL) 30.2 ± 10.4 33.9 ± 14.9 35.9 ± 15.0 0.095
LVEF (%) 64 ± 5 63 ± 7 62 ± 16 0.325
Indexed left atrial volume (mL/m2) 26.5 ± 8.6 35.3± 12.5a 44.9 ± 19.6a,b <0.001
Mitral E/A ratio 0.9 ± 0.3 0.9 ± 0.3 1.0 ± 0.9 0.363
Average E/e’ 7.4 ± 1.8 12.9 ± 5.6a 13.5 ± 5.2a <0.001
TTPG (mmHg) 17 ± 8 29 ± 11a 31 ± 12a <0.001
TAPSE (mm) 22 ± 3 23 ± 4 23 ± 3 0.747
RV s’ (cm/s) 13 ± 3 13 ± 3 12 ± 3a 0.014
Right atrial volume (mL) 32.7 ± 10.8 40.3 ± 20.0 44.3 ± 28.7a 0.015
LV-RV longitudinal strain
RV GLS (%) 20.3 ± 4.5 19.7 ± 3.6 20.2 ± 4.0 0.285
LV GLS (%) 20.7 ± 2.1 18.5 ± 2.8a 17.4 ± 2.8a,b <0.001
Continued
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AS group (n 5 97)
Symptomatic
AS group (n 5 114)
P-value
Endocardial LS (%) 23.4 ± 2.5 21.1 ± 3.2a 19.6 ± 3.4a,b <0.001
Epicardial LS (%) 18.3 ± 1.8 16.2 ± 2.5a 15.4 ± 2.6a,b <0.001
Gradient endocardial-epicardial LS 5.1 ± 1.1 4.8 ± 1.1 4.3 ± 1.6a,b 0.001
Values are expressed as n (%) or mean ± SD.
AS, aortic stenosis; BMI, body mass index; BNP, brain natriuretic peptide; BSA, body surface area; EF, ejection fraction; GLS, global longitudinal strain; LV, left ventricle; RV, right
ventricle; TTPG, trans-tricuspid pressure gradient; Zva, valvulo-arterial impedance.
aP < 0.05 vs. controls.
bP < 0.05 vs. asymptomatic group.
Figure 1 GLS (mid-myocardial), endocardial, and epicardial longitudinal strain in controls, asymptomatic and symptomatic severe AS patients.
...................................................................... ......................................................................
....................................................................................................................................................................................................................
Table 2 Univariable and multivariable logistic regression analyses of clinical and echocardiographic parameters asso-
ciated with symptoms (Model 1)
Parameters Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
Body mass index 1.070 1.011–1.132 0.020
BNP 1.425 1.097–1.851 0.008
LV mass index 1.023 1.011–1.036 <0.001
Normal geometry 2.748 1.200–6.291 0.017
Concentric remodelling 2.485 1.274–4.849 0.008 2.294 1.021–5.150 0.044
Concentric hypertrophy 3.293 1.796–6.037 <0.001
Mean pressure gradient 1.021 1.000–1.046 0.047
Indexed aortic valve area 0.024 0.001–0.538 0.019
Indexed left atrial volume 1.044 1.021–1.067 <0.001 1.035 1.010–1.061 0.006
GLS 1.124 1.032–1.223 0.007
Endocardial LS 1.118 0.039–1.204 0.003 1.150 1.032–1.282 0.012
BNP, brain natriuretic peptide; CI, confidence interval; GLS, global longitudinal strain; LS, longitudinal strain; LV, left ventricle; OR, odds ratio.
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subendocardial LS of 21% in patients with severe AS was associated
with symptoms with a sensitivity of 70% and a specificity of 65% [area
under the curve (AUC) = 0.692, P < 0.001].
Predictors of clinical outcome
After a median follow-up period of 22 months (interquartile range:
7–51 months), 145 patients with severe aortic stenosis underwent
AVR (transcatheter AVR = 38, surgical replacement = 107), and 33
patients died of a cardiovascular event (after AVR = 20, heart failure
= 4, sudden death = 7, cardiac tamponade = 1, stroke = 1). In the uni-
variable Cox-regression analysis, patients who died were older
(P = 0.002), had higher values of BNP and LV mass (P < 0.001),
greater LV end-diastolic diameter (P = 0.004), and LV volumes
(P = 0.044 for end-diastolic, P = 0.015 for end-systolic), right and left
atrial volumes (P < 0.001), diastolic dysfunction and pulmonary
hypertension (P < 0.001). In addition, significant correlations between
GLS (P = 0.006), endocardial LS (P = 0.003), epicardial LS (P = 0.045)
and mortality were observed. For the other parameters, including se-
verity of AS, no significant correlations with the outcome were found
(P > 0.1 for all) (Table 4). On multivariable Cox-regression analysis,
age (P = 0.029), BNP values (P = 0.003), LV mass index (P = 0.0065),
LV end-systolic volume (P = 0.012), and endocardial LS (P = 0.0057)
emerged as independently associated with cardiovascular death. The
best endocardial LS values associated with outcome was 20.6% (sen-
sitivity 70%, specificity 52%, AUC = 0.626, P = 0.022) (Figure 3A). The
cumulative event rate for cardiovascular death was significant higher
in AS patients with more impaired endocardial LS (<20.6%)
compared to those with preserved endocardial LS (>_20.6%)
(21.6% vs. 11.3% at 5-year follow-up, respectively; log-rank P = 0.035)
(Figure 3B).
During a median period of 30 months (interquartile range: 14–
36 months), 9 (9%) out of the 97 asymptomatic patients died from
cardiovascular deaths (most of them after symptoms development).
These patients had higher values of BNP, more pronounced cardiac
chambers remodelling, diastolic dysfunction, and pulmonary hyper-
tension. Both GLS (16.9 ± 2.9 vs. 18.2± 2.8, P = 0.031) and endocar-
dial LS (19.1± 3.3 vs. 20.7 ± 3.3, P = 0.02) but not epicardial LS
(15.2 ± 2.8 vs. 15.9 ± 2.5, P = 0.10) were reduced in patients who
died.
Discussion
In patients with severe AS and preserved LVEF, the present study
demonstrates that: (i) GLS (mid-myocardial), as well as endocardial
and epicardial LS values are lower in patients with severe AS as
...................................................................... ......................................................................
....................................................................................................................................................................................................................
Table 3 Univariable and multivariable logistic regression analysis of clinical and echocardiographic parameters associ-
ated with symptoms (Model 2)
Parameters Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
Body mass index 1.070 1.011–1.132 0.020
BNP 1.425 1.097–1.851 0.008
LV mass index 1.023 1.011–1.036 <0.001
Normal geometry 2.748 1.200–6.291 0.017
Concentric remodelling 2.485 1.274–4.849 0.008 2.429 1.084–5.445 0.040
Concentric hypertrophy 3.293 1.796–6.037 <0.001
Mean pressure gradient 1.021 1.000–1.046 0.047
Indexed aortic valve area 0.024 0.001–0.538 0.019
Indexed left atrial volume 1.044 1.021–1.067 <0.001 1.172 1.032–1.332 0.015
GLS 1.124 1.032–1.223 0.007 1.036 1.010–1.032 0.006
Epicardial LS 1.118 0.039–1.204 0.003
BNP, brain natriuretic peptide; CI, confidence interval; GLS, global longitudinal strain; LS, longitudinal strain; LV, left ventricle; OR, odds ratio.
Figure 2 ROC curve of endocardial longitudinal strain associated
with symptoms in patients with severe AS.
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..compared to controls; (ii) symptomatic patients with severe AS have
decreased values of all layers of LV strain compared to asymptomatic
patients with similar LVEF; (iii) endocardial LS is more sensitive than
GLS and epicardial LS to characterize the symptomatic status of AS
patients; (iv) endocardial LS is an independent predictor of cardiovas-
cular outcome.
Multilayer strains and symptoms
Symptom development and a LVEF <50% are the main triggers for
AVR in patients with severe AS. However, symptoms are subjective,
patients may be unable to perform an exercise test to characterize
them, and a LVEF <50% already demonstrates advanced myocardial
involvement (i.e. extensive myocardial fibrosis) with limited
...................................................................... ...............................................................
....................................................................................................................................................................................................................
Table 4 Univariable and multivariable predictors of cardiovascular mortality
Parameters Univariable Multivariable
HR 95% CI P-value HR 95% CI P-value
Age 1.067 1.025–1.110 0.002 1.12 1.017–1.32 0.029
Body mass index 1.012 0.939–1.090 0.762
Body surface area 1.972 0.357–10.905 0.436
Systolic arterial pressure 0.986 0.967–1.005 0.142
Diastolic arterial pressure 0.968 0.934–1.004 0.084
LogBNP 2.160 1.457–3.201 <0.001 2.12 1.03–4.45 0.003
Diabetes mellitus 0.606 0.294–1.250 0.175
Hypertension 0.719 0.296–1.747 0.466
Hypercholesterolaemia 1.336 0.655–2.726 0.426
Current smoking 1.172 0.452–3.042 0.744
Coronary artery disease 0.334 0.155–0.722 0.005
LV mass index 1.022 1.009–1.035 0.001 1.06 1.017–1.12 0.0065
Interventricular septum 1.092 0.917–1.300 0.325
LV posterior wall 1.173 0.949–1.451 0.141
LV end-diastolic diameter 1.087 1.027–1.151 0.004
LV end-systolic diameter 1.060 0.998–1.125 0.059
Relative wall thickness 0.343 0.009–13.159 0.565
Normal geometry 2.534 0.602–10.660 0.205
Concentric remodelling 1.187 0.507–2.782 0.693
Concentric hypertrophy 0.735 0.354–1.523 0.407
Eccentric hypertrophy 0.701 0.267–1.839 0.471
Mean pressure gradient 0.989 0.963–1.016 0.425
Peak aortic velocity 0.691 0.404–1.182 0.177
Aortic valve area 4.607 0.567–37.437 0.153
Indexed aortic valve area 22.554 0.325–1565 0.150
Indexed stroke volume 1.009 0.973–1.046 0.646
Zva 0.864 0.578–1.292 0.476
LV end-diastolic volume 1.009 1.000–1.018 0.044
LV end-systolic volume 1.025 1.005–1.045 0.015 1.107 1.02–1.20 0.012
LV EF 0.951 0.900–1.005 0.073
Indexed left atrial volume 1.034 1.020–1.049 <0.001
Average E/e’ 1.096 1.045–1.149 <0.001
TTPG (mmHg) 1.052 1.026–1.079 <0.001
TAPSE (mm) 0.934 0.848–1.028 0.163
RV s’ 0.857 0.716–1.025 0.092
Right atrial volume 1.019 1.009–1.029 <0.001
RV GLS 1.008 0.963–1.054 0.744
LV GLS 1.212 1.057.1.390 0.006
Endocardial LS 1.190 10.061–1.334 0.003 2.75 1.33–5.69 0.0057
Epicardial LS 1.164 1.003–1.351 0.045
Gradient endocardial-epicardial LS 1.308 1.101–1.552 0.002
AS, aortic stenosis; BNP, brain natriuretic peptide; CI, confidence interval; EF, ejection fraction; GLS, global longitudinal strain; HR, hazard ratio; LS, longitudinal strain; LV, left
ventricle; TTPG, trans-tricuspid pressure gradient; Zva, valvulo-arterial impedance.
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..reversibility after AVR.20,21 In the HAVEC registry, patients with
LVEF between 50% and 59% had less favourable outcomes and expe-
rienced more heart failure-related deaths than those with LVEF
>60%, even after AVR.4 Reduced LV GLS is an early marker of
impaired contractile function when LVEF is still preserved and is also
associated with the presence of myocardial fibrosis.22 Recent series
in patients with AS have also linked GLS with subsequent cardiac
events and worsening of strain abnormalities as AS progresses des-
pite the lack of a simultaneous fall in LVEF.23–29 Spatial configurations
of ventricular myocardial fibres in the subendocardial and subepicar-
dial layers provide sequential contractile activity of the ventricle and
contribute to LV GLS. The endocardium undergoes greater dimen-
sional changes (both thickening and shortening) during systole than
does the epicardium in healthy myocardium. In AS, as the subendo-
cardial fibres are more sensitive to microvascular ischaemia (suben-
docardial blood flow maldistribution related to LV hypertrophy and
increased wall stress) and fibrosis, the longitudinal function is likely
the first to be altered.30–32 However, as the AS progresses, all myo-
cardial layers are gradually affected but to a different extent. Cho et
al.33 reported lower epicardial, mid-wall, and endocardial LS in 45
patients with severe AS compared to 18 healthy controls, and corre-
lated LS with LV mass index, LVEF, left atrial volume, and N-terminal
pro-B-type natriuretic peptide.33 In 36 AS patients, Ozawa et al.12
correlated the impairment of multilayer LS, particularly of endocar-
dial LS, with the severity of AS. The present study confirms and
extends these findings in a larger population and provides new
insights into the relationship between regional strain impairment and
symptoms in AS. As observed, all layer-specific strains were
decreased in patients with AS as compared to controls. However,
the reduction in regional strains, particularly of endocardial LS, was
more pronounced in symptomatic patients. Hence, the assessment
of multilayer strains appears to be promising and may complement
conventional echocardiographic parameters (e.g. LV remodelling, left
atrial volume) to discriminate the symptomatic status in AS.
Multilayer strains and outcomes
Comorbidities are frequent in patients with AS (e.g. age, coronary ar-
tery disease) and increase the overall cardiovascular risk profile of
patients. Biomarkers have consistently shown to be associated with
patient outcome. Higher BNP values are associated with increased
mortality risk. Echocardiography also plays a major predictive role in
AS.32,34 As reported, the severity of AS, the degree of LV hyper-
trophy and remodelling, the diastolic burden (e.g. increased in LV fill-
ing pressure, left atrial enlargement), the augmented pulmonary
pressures and dilated right atrium, and the extent of regional LV sys-
tolic dysfunction as estimate by GLS are all potential predictors of
poor outcome. These data are also confirmed in our study in which
we also show a prognostic value of layer-specific strains. Alteration of
endocardial LS was strongly and independently associated with higher
cardiovascular mortality rate in patients with AS and preserved LVEF.
Reduced endocardial strain was observed in patients who died re-
gardless of the symptomatic status at the entry point. Consequently,
LVEF, which only takes into account the LV chamber or wall thick-
ness as a whole, is insufficient to estimate the degree of dysfunction
within the different layers of the myocardial wall, which represents a
more sensitive marker of myocardial involvement and outcome. An
endocardial LS below 20.6% yielded the strongest predictive
Figure 3 ROC curve of endocardial longitudinal strain associated with cardiovascular death in patients with severe AS (A). Kaplan–Meier estimates
for cardiovascular death during follow-up in patients with severe AS divided into two groups according to baseline endocardial longitudinal strain:
more impaired (<20.6%, green line) vs. more preserved (>_20.6%, blue line) (B).
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accuracy for cardiovascular death, even if with moderate accuracy,
likely due to low hard event rates. Further prospective studies with
larger number of patients could confirm the data and determine the
exact role of endocardial LS in predicting cardiovascular events.
Limitations
This study has some limitations. We included in the study only
patients with severe AS based on aortic valve area and preserved LV
ejection fraction. The sub-categorization of AS according to flow-
gradient pattern was not performed. The presence of patients with
coronary artery disease could affect our data. However, coronary ar-
tery disease incidence was similar in both groups with and without
symptoms, and patients with wall motion abnormalities were pre-
ventively excluded from the analysis. The gradient of strain across the
myocardium is a nonlinear phenomenon, and the definition of the
layers is arbitrary and is based on simple division into three parts.
Because the spatial resolution of ultrasound is limited, there will al-
ways be a certain degree of overlap. Despite interobserver and intra-
observer reproducibility of LV GLS have demonstrated to be
comparable with conventional echocardiography parameters, the
variability of LS measurement related to ultrasound system and the
software for the off-line analysis could represent a limitation. The de-
cision to perform surgery was made by individual cardiologists in
charge of the patients. Serial echocardiographic assessment over
time was not performed.
Conclusions
In severe AS, LS impairment involves all myocardial layers and is
more prominent in the endocardial layer. This impairment becomes
even more evident in the advanced phases of the disease when the
symptoms occur. Regardless of the symptomatic status, reduced LS
conveys a worse outcome. Further studies are needed to better de-
termine the role of endocardial LS in predicting the progression of
aortic valve disease and the occurrence of cardiovascular events.
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21. Treibel TA, López B, González A, Menacho K, Schofield RS, Ravassa S et al.
Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-
invasive study in 133 patients. Eur Heart J 2018;39:699–709.
22. Hoffmann R, Altiok E, Friedman Z, Becker M, Frick M. Myocardial deformation
imaging by two-dimensional speckle-tracking echocardiography in comparison to
late gadolinium enhancement cardiac magnetic resonance for analysis of myocar-
dial fibrosis in severe aortic stenosis. Am J Cardiol 2014;114:1083–8.
23. Ng AC, Delgado V, Bertini M, Antoni ML, van Bommel RJ, van Rijnsoever EP
et al. Alterations in multidirectional myocardial functions in patients with aortic
stenosis and preserved ejection fraction: a two-dimensional speckle tracking ana-
lysis. Eur Heart J 2011;32:1542–50.
24. Kearney LG, Lu K, Ord M, Patel SK, Profitis K, Matalanis G et al. Global longitu-
dinal strain is a strong independent predictor of all-cause mortality in patients
with aortic stenosis. Eur Heart J Cardiovasc Imaging 2012;13:827–33.







aging/article-abstract/21/4/408/5556417 by  plancellotti@






















25. Ng ACT, Prihadi EA, Antoni ML, Bertini M, Ewe SH, Ajmone Marsan N et al. Left
ventricular global longitudinal strain is predictive of all-cause mortality independ-
ent of aortic stenosis severity and ejection fraction. Eur Heart J Cardiovasc Imaging
2018;19:859–67.
26. Donal E, Thebault C, O’Connor K, Veillard D, Rosca M, Pierard L et al. Impact of
aortic stenosis on longitudinal myocardial deformation during exercise. Eur J
Echocardiogr 2011;12:235–41.
27. Vollema EM, Sugimoto T, Shen M, Tastet L, Ng ACT, Abou R et al. Association
of left ventricular global longitudinal strain with asymptomatic severe aortic sten-
osis natural course and prognostic value. JAMA Cardiol 2018;3:839–47.
28. Magne J, Cosyns B, Popescu BA, Carstensen HG, Dahl J, Desai MY et al.
Distribution and prognostic significance of left ventricular global longitudinal
strain in asymptomatic significant aortic stenosis: an individual participant data
meta-analysis. Eur Heart J Cardiovasc Imaging 2019;12:84–92.
29. Dahl JS, Magne J, Pellikka PA, Donal E, Marwick TH. Assessment of subclinical
left ventricular dysfunction in aortic stenosis. JACC Cardiovasc Imaging 2019;12:
163–71.
30. Garcia D, Camici PG, Durand LG, Rajappan K, Gaillard E, Rimoldi OE et al.
Impairment of coronary flow reserve in aortic stenosis. J Appl Physiol 2009;106:
113–21.
31. Rajappan K, Rimoldi OE, Dutka DP, Ariff B, Pennell DJ, Sheridan DJ et al.
Mechanisms of coronary microcirculatory dysfunction in patients with aortic
stenosis and angiographically normal coronary arteries. Circulation 2002;105:
470–6.
32. Lancellotti P, Donal E, Magne J, Moonen M, O’Connor K, Daubert JC et al. Risk
stratification in asymptomatic moderate to severe aortic stenosis: the import-
ance of the valvular, arterial and ventricular interplay. Heart 2010;96:1364–71.
33. Cho EJ, Park SJ, Kim EK, Lee GY, Chang SA, Choi JO et al. Effects of increased
left ventricular wall thickness on the myocardium in severe aortic stenosis with
normal left ventricular ejection fraction: two- and three-dimensional multilayer
speckle tracking echocardiography. Echocardiography 2017;34:511–22.
34. Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA et al.
Outcomes of patients with asymptomatic aortic stenosis followed up in heart
valve clinics. JAMA Cardiol 2018;3:1060–8.







aging/article-abstract/21/4/408/5556417 by  plancellotti@
chu.ulg.ac.be on 21 M
arch 2020
